Interim data from ENERGY 3 trial highlight INZ-701's potential to modify disease course in ENPP1 Deficiency, with sustained ...

Individuals with type 2 diabetes or a higher BMI may face a reduced risk of developing GCA, while a history of cardiovascular disease may increase this risk.

CitiusTech's John Edward discusses how AI can transform healthcare despite imperfect data, exploring Agentic AI, data quality ...

Results from a Phase 1 study of GT-02287 in healthy volunteers demonstrated favorable safety and tolerability, plasma and CNS ...

Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type ...

Kennesaw State University senior Kaden Buford likes being hands-on with exercise science, immersing in a clinical environment ...

Recent advances in developing cellular therapies, a broad group of strategies that use cells to treat disease, have shown efficacy in some types of blood c | Cancer ...

Alzheimer’s disease stands as the most widespread form of dementia globally, increasingly burdening families, healthcare systems, and societies as populations age. Although current treatments, ...

Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) Nearly 50 Sites Activated Across U.S. with Strong Enthusiasm ...

Objective Growing evidence suggests that coeliac disease (CeD) is more common in patients with inflammatory bowel disease ...

Q1 2025 Earnings Call Transcript May 12, 2025 Coherus BioSciences, Inc. misses on earnings expectations. Reported EPS is ...

Feasibility endpoint achieved; rapid Ki-67 suppression and substantial MRI-confirmed tumor shrinkage observed with favorable safety profile SEATTLE, May 14, 2025 /PRNewswire/ -- Atossa Therapeutics ...